-
09:47:37 PM

GSK Stock News

09/15/23 7:26 PM
NYSE : GSK
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
GSK plc today announced that the US Food and Drug Administration has approved Ojjaara for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, in adults with anemia. Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 inhibitor. To date, it is the only approved medicine for...
RHEA-AI
negative
09/05/23 8:00 AM
NYSE : GSK
conferences
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
GSK plc and YMCA of the USA will host GSK’ s Sideline RSV“ Community Conversations” event series as part of their campaign efforts to raise awareness about RSV infection in older adults. The events will take place at four YMCA locations across the country, joined by GSK’ s campaign spokesperson Earvin“ Magic” Johnson, to help spark important conversations about RSV, a...
RHEA-AI
neutral
08/17/23 8:00 AM
NYSE : GSK
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
GSK plc today announced that AREXVY is now available in the US at all major retail pharmacies. In June, the Advisory Committee on Immunization Practices recommended that persons 60 years of age and older may receive a single dose of RSV vaccine, using shared clinical decision making. Shared clinical decision making empowers patients, in consultation with...
RHEA-AI
negative
07/31/23 2:42 PM
NYSE : GSK
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
GSK plc today announced that the US Food and Drug Administration has approved Jemperli in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, as determined by an FDA-approved test, or microsatellite...
RHEA-AI
neutral
06/21/23 8:26 PM
NYSE : GSK
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
GSK plc today announced that the US Centers for Disease Control and Prevention’ s Advisory Committee on Immunization Practices voted in favor of recommending the use of AREXVY in adults aged 60 and older using shared clinical decision making. Shared clinical decision making empowers patients in consultation with their healthcare providers to determine...
RHEA-AI
neutral
06/21/23 8:00 AM
NYSE : GSK
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
GSK plc today announced new data from the AReSVi-006 phase III trial evaluating the efficacy of a single dose of AREXVY against lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older over multiple RSV seasons and after annual revaccination. This press release features multimedia. View the full release here:...
RHEA-AI
negative